This site is intended for Healthcare professionals only.
×

Cadila Healthcare arm gets USFDA nod to market Ranitidine injection


Cadila Healthcare arm gets USFDA nod to market Ranitidine injection

NEW DELHI: Drug firm Cadila Healthcare on Tuesday said its subsidiary has received approval from the US health regulator to market Ranitidine injection, used to treat stomach and duodenal (intestinal) ulcers.

Liva Pharmaceuticals, a wholly-owned subsidiary of Cadila Healthcare, has received approval from the US Food and Drug Administration (USFDA) for its supplemental abbreviated new drug application, Ranitidine Injection USP, 25 mg/mL, 2 mL single-dose vials and 6 mL multi-dose vials, Cadila Healthcare said in a BSE filing.

Cadila Healthcare said the product will be manufactured at Liva Pharma’s manufacturing facility at Vadodara and is the first product to be approved from this site for marketing in the US.

The company has more than 237 approvals and has so far filed over 340 abbreviated new drug applications (ANDAs) since it commenced filings in 2003-04.

Read Also: Cadila Healthcare subsidiary gets 5 observations from USFDA

The following two tabs change content below.
MD Team

MD Team

At Medical Dialogues, we are a team of young professionals strongly advocating of the transparency in the medical sector through the free flow of medical information, health and medical news. MD Team covers a variety of news related to the healthcare, pharma and medical device industry in India. Our team can be contacted at editorial@medicaldialogues.in Contact no. 011-43720751


Source: PTI
0 comment(s) on Cadila Healthcare arm gets USFDA nod to market Ranitidine injection

Share your Opinion Disclaimer

Sort by: Newest | Oldest | Most Voted